SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

Inclusion Criteria: * Age \>=18 years, either sex, any race. * Eastern Cooperative Oncology group performance status of 0 or 1. * Adequate hematologic, renal, and hepatic organ function and laboratory parameters. * For subjects with MCL: * Diagnosis of MCL according to the World Health Organization (WHO) criteria. * Received at least one prior chemotherapeutic regimen, but no more than two regimens including stem cell transplantation.. * Measurable or assessable disease by the Revised Response Criteria for Malignant Lymphoma. * For subjects with B-CLL * Documented B-CLL according to the National Cancer Institute Working Group (NCI-WG) criteria. * Received at least one prior alkylating agent-based regimen and one fludarabine- or pentostatin-containing regimen, but must not have received more than two prior regimens. * Measurable or assessable disease by NCI-WG criteria. Exclusion Criteria: * Known central nervous system involvement of MCL or B-CLL. * Previous treatment with SCH 727965 or other cyclin-dependent kinase inhibitors. * For MCL, previous treatment with bortezomib. * For B-CLL, previous treatment with alemtuzumab. * Known HIV infection. * Known active hepatitis B or C.